Keytruda combination improves OS for HER2-positive advanced gastric cancer in phase III trial

Circadian clock can be leveraged to enhance cancer immunotherapy

A multidisciplinary research team at the University of California, Irvine, has revealed that the circadian clock can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy.

Keytruda improves OS for high-risk early-stage TNBC in phase III trial

The phase III KEYNOTE-522 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, met its overall survival endpoint, in combination with chemotherapy as pre-operative treatment and then continuing as a single agent after surgery for the treatment of patients with high-risk early-stage triple-negative breast cancer.

Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study

Iovance Biotherapeutics Inc. a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, has updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting.

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone. The work will be presented at the 2024 ASCO Annual Meeting.